Analysis of nationwide availability of negotiated drugs in China's National Reimbursement Drug List.

ABSTRACT:

Objective

This study aims to evaluate the availability of Price-Negotiated Drugs under China's National Reimbursement Drug List in healthcare institutions and designated retail pharmacies.

Methods

This cross-sectional study uses data from the National Health Insurance Service Platform (extracted in September 2025) to evaluate the availability of 383 National Negotiated Drugs in healthcare institutions and retail pharmacies nationwide. According to the World Health Organization (WHO)/Health Action International (HAI) framework, availability was assessed based on the availability rate and allocation rate. Spearman's rank correlation test (α = 0.05) was applied to examine associations between drug availability and factors including the timing of formulary inclusion, per

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC12824015 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature